Zobrazeno 1 - 10
of 31
pro vyhledávání: '"E Villamañán Bueno"'
Autor:
C, Cisneros-Serrano, M, Jorge Rial, A, Gómez-Bastero-Fernández, J, Manuel Igea, A, Martínez-Meca, L C, Fernández-Lisón, V, López-Carrasco, E, Villamañán-Bueno, M J, Plá-Martí, E, Chiner
Publikováno v:
Revista Clínica Española (English Edition). 223:154-164
Biologic therapies are known to reduce exacerbations and improve severe uncontrolled asthma management. The at-home administration of biologics has increased during the COVID-19 pandemic, but the characteristics of severe uncontrolled asthma patients
Autor:
C. Cisneros-Serrano, M.J. Rial, A. Gómez-Bastero-Fernández, J.M. Igea, A. Martínez-Meca, L.C. Fernández-Lisón, V. López-Carrasco, E. Villamañán-Bueno, M.J. Plá-Martí, E. Chiner
Publikováno v:
Revista Clínica Española. 223:154-164
Autor:
P Mariscal Aguilar, L Gómez Carrera, C Carpio Segura, G Bonilla Hernán, M I Torres Sánchez, M Fernández Velilla-Peña, E Villamañán Bueno, R Regojo Zapata, J Pavón Guede, C Prados Sánchez, R Álvarez-Sala Walther
Publikováno v:
12.01 - Idiopathic interstitial pneumonias.
Autor:
P Mariscal Aguilar, D Laorden Escudero, A L Qasem Moreno, T Lázaro Miguel-Sin, M Jiménez González, A Moreno Fernández, F Arnalich Fernández, A Borobia Fernández, J Pavón Guede, R Camperos Moreno, A Buño Soto, R Álvarez-Sala Walther, L Gómez Carrera, C Prados Sánchez, E Villamañán Bueno, V Rey Mauleón, V Arnalich Montiel, S Alcolea Batres, I Fernández Navarro, C Carpio Segura
Publikováno v:
01.01 - Clinical problems - no related to asthma or COPD.
Autor:
Inmaculada Jiménez-Nácher, E Villamañán Bueno, M Moreno Palomino, E Rodriguez Martin, A Arancón Pardo, C Sobrino Jiménez, M. A. González Fernández, C Bilbao Gómez-Martino, F Moreno Ramos, M García-Trevijano, A Herrero Ambrosio
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Currently, several disease modifying drugs are approved for multiple sclerosis (MS). IFNβ-1b, IFNβ-1a, pegIFNβ-1a, glatiramer acetate, teriflunomide and dimethylfumarate are indicated for firstline therapy. Secondline tre
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alejandro Balsa, C. Plasencia Rodriguez, E Villamañán Bueno, I Jiménez Nácher, F Moreno Ramos, A Herrero Ambrosio
Publikováno v:
Saturday, 16 JUNE 2018.
Background Spending on biological agents has risen dramatically in Spanish hospitals due to the drugs’ high cost and the increased prevalence of spondyloarthritis. Objectives To calculate and compare the annual cost per patient with spondyloarthrit
Autor:
S Feliú Torres, A Sierra Muñoz, A Herrero Ambrosio, G. Casado Abad, E Villamañán Bueno, N Rodríguez Salas, L Sánchez Rubio Ferrández
Publikováno v:
Annals of Oncology. 30:v672-v673
Background Colon cancer presents at high incidence and its treatment generates an important economic impact in hospitals. In Spain, it is mandatiory for the sponsors of clinical trials to supply the investigational drugs without charge to the nationa
Autor:
M Freire-González, C Lara-Cátedra, M Ruano-Encinar, E Villamañán-Bueno, C Sobrino-Jiménez, C Jiménez-Vicente, P Gabaldón-Garnica, Alicia Herrero-Ambrosio
Publikováno v:
Drug information and pharmacotherapy.
Background Respiratory diseases are a worldwide major health problem, specially chronic obstructive pulmonary disease (COPD) and respiratory infections. Treatment usually involves inhaled drugs that are essential in asthma and COPD. Purpose To analys
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.